Dexpramipexole

CAS No.	104632-28-2	Cat. No.	BCP12512
Name	Dexpramipexole
Synonyms	(R)-Pramipexole;KNS-760704; KNS 760704; KNS760704;R-(+)-Pramipexole;
Formula	C10H17N3S	M. Wt	211.33

Description	Dexpramipexole, also known as KNS-760704 and (R)-Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water-soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well tolerated in human subject testing. KNS-760704 is the enantiomer of pramipexole, and has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress. A 2010 Phase II clinical trial involving 102 patients showed a slowing of ALS disease progression.[5] In January 2013, Biogen Idec announced that it was discontinuing its development of dexpramipexole in ALS due to lack of efficacy in a Phase III study.
Pathways	Neuro Signaling Pathway GPCR/G Protein
Targets	Dopamine Receptor

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.